Lincoln Pharmaceuticals has informed that the Meeting of the Board of Directors of the Company is scheduled to be held on May 30, 2017, to consider the approval and adoption of Audited Consolidated and Standalone Financial results of the Company for the Quarter and Year ended on March 31, 2017, Recommendation of dividend on Equity Shares of the Company for the Financial Year ended on March 31, 2017, if any. In view of above, the trading window will remain close for the Promoters, Directors, Insiders, Designated Persons and the Connected Persons from May 20, 2017 and shall reopen after the expiry of 48 hours from the time the result becomes generally available.
The above information is a part of company’s filings submitted to BSE.
